2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Brain Neoplasms
12
Cognitive Dysfunction
4
Radiation Injuries
3
Neoplasms
3
Multiple Myeloma
3
Glioma
3
Breast Neoplasms
3
Lymphoma, B-Cell
2
Lymphoma
2
Glioblastoma
2
Fatigue
2
Colorectal Neoplasms
2
Astrocytoma
2
Triple Negative Breast Neoplasms
1
Stroke
1
Sarcoma
1
Prostatic Neoplasms
1
Pituitary Neoplasms
1
Parkinson Disease
1
Osteosarcoma
1
Oligodendroglioma
1
Neurotoxicity Syndromes
1
Neurofibromatosis 1
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Meningioma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Interventions
lutetium Lu 177 dotatate
40
Everolimus
35
Magnetic Resonance Spectroscopy
15
lanreotide
14
gallium Ga 68 dotatate
13
Temozolomide
13
Octreotide
12
Nivolumab
12
pembrolizumab
11
Capecitabine
11
surufatinib
10
177Lu-octreotide, DOTA(0)-Tyr(3)-
10
cabozantinib
9
Positron Emission Tomography Computed Tomography
9
3-Iodobenzylguanidine
9
Sunitinib
8
Specimen Handling
7
Carboplatin
7
telotristat ethyl
6
pasireotide
6
amino-acid, glucose, and electrolyte solution
6
Somatostatin
6
Lutetium-177
6
90Y-octreotide, DOTA-Tyr(3)-
6
lenvatinib
5
Ipilimumab
5
Ga(III)-DOTATOC
5
Fluorodeoxyglucose F18
5
Etoposide
5
Cisplatin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
Neuropsychological Tests
×
Clear all
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled